The 'three-parent baby' fertility doctor needs to stop marketing the procedure, FDA says
By Rachel Becker,
The Verge [cites Marcy Darnovsky]
| 08. 05. 2017
On Friday, FDA sent him a letter notifying him of his violations
The doctor who created a genetically modified “three-parent baby” has been reprimanded by the Food and Drug Administration for aggressively marketing the unapproved experimental procedure.
John Zhang, CEO of the New Hope Fertility Center in New York, famously combined the DNA of three people to help a mother who was a carrier for a genetic disease conceive an apparently healthy baby boy last year. Now, Zhang and his company are marketing the pricy procedure as the “first proven treatment for certain genetic disorders and a successful solution to age-related infertility.”
However, the FDA does not allow clinical research in people that would involve genetically modifying an embryo. And because Zhang’s technique and the one child it produced are both still in their infancy, we don’t know how well the treatment really works, or if it comes with any unforeseen consequences. On Friday, the FDA posted a letter to Zhang online, informing him that marketing the procedure is illegal, since the FDA hasn’t given him permission to...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
